Enhanced resection and improved survival in murine neuroblastoma (C1300-NB) after preoperative immunotherapy

Advanced neuroblastoma treated with standard chemotherapy has a poor prognosis. Combination immunotherapy for murine neuroblastoma with retinyl palmitate, low-dose cyclophosphamide, and interleukin-2 resulted in increased survival, impaired tumor growth, easier surgical resection, and increased clas...

Full description

Saved in:
Bibliographic Details
Published inJournal of pediatric surgery Vol. 26; no. 4; pp. 381 - 388
Main Authors Fowler, Carol L., Brooks, Stephen P., Squire, Roly, Rich, Gary A., Rossman, Jon E., Finegold, Milton J., Allen, James E., Cooney, Donald R.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.1991
Subjects
Animals
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Female
Histocompatibility Antigens Class I - biosynthesis
Immunotherapy
Interleukin-2 - administration & dosage
Mice
Mice, Inbred A
Neuroblastoma - immunology
Neuroblastoma - pathology
Neuroblastoma - surgery
Neuroblastoma - therapy
Preoperative Care
Recombinant Proteins - administration & dosage
Survival Rate
Vitamin A - administration & dosage
Vitamin A - analogs & derivatives
cyclophosphamide
interleukin-2
retinyl palmitate
Neuroblastoma
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Advanced neuroblastoma treated with standard chemotherapy has a poor prognosis. Combination immunotherapy for murine neuroblastoma with retinyl palmitate, low-dose cyclophosphamide, and interleukin-2 resulted in increased survival, impaired tumor growth, easier surgical resection, and increased class I expression or tumor cells. Preoperative immunotherpay may be useful in treatment of advanced human neuroblastoma.
ISSN:0022-3468
1531-5037
DOI:10.1016/0022-3468(91)90983-Z